Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
Intervalo de año de publicación
1.
iScience ; 26(8): 107380, 2023 Aug 18.
Artículo en Inglés | MEDLINE | ID: mdl-37575182

RESUMEN

Immunization of pregnant women with Group B Streptococcus (GBS) capsular polysaccharide (CPS) conjugate vaccine (CV) could protect young infants against invasive GBS disease. We evaluated the immunogenicity of investigational five GBS monovalent (serotypes Ia, Ib, II, III, and V) CPS-tetanus toxoid (TT)-CV with adjuvant and GBS pentavalent CPS-TT-CV with adjuvant (GBS5-CV-adj) and without adjuvant (GBS5-CV-no-adj), in Balb/c mice. Aluminum phosphate was the adjuvant in the formulations, where included. The homotypic immunoglobulin G (IgG) geometric mean concentration (GMC) and opsonophagocytic activity (OPA) geometric mean titer (GMT) did not differ after the third dose of the GBS5-CV-adj vaccine compared with the monovalent counterparts for all five serotypes. The GBS5-CV-adj induced higher post-vaccination serotype-specific IgG GMCs and OPA GMTs compared to GBS5-CV-no_adj. The GBS5-CV with and without adjuvant should be considered for further development as a potential vaccine for pregnant women to protect their infants against invasive GBS disease.

2.
Vaccine ; 40(42): 6055-6063, 2022 10 06.
Artículo en Inglés | MEDLINE | ID: mdl-36096970

RESUMEN

No vaccines are currently licensed against Group B streptococcus (GBS), an important cause of morbidity and mortality in babies and adults. Using a mouse model, and in vitro opsonophagocytosis and colonisation assays, we evaluated the potential of a sublingually-administered polysaccharide-conjugate vaccine against GBS serotype III. Sublingual immunisation of mice with 10 µg of GBS conjugate vaccine once a week for 5 weeks induced a substantial systemic IgG anti-polysaccharide response which was similar to the level induced by subcutaneous immunsation. In addition, sublingual immunisation also induced mucosal (IgA) antibody responses in the mouth, intestines and vagina. Immune sera and intestinal washes were functionally active at mediating killing of the homologous GBS serotype III in an opsonophagocytosis assay. In addition, intestinal and vaginal washes inhibited the colonisation of mouse vaginal epithelial cells by the vaccine homologous strain. These results suggest that, in addition to the induction of high levels of IgG antibodies that could be transduced from the immunised mother to the foetus to protect the newborn against GBS infection, sublingual immunisation can elicit a substantial mucosal antibody response which might play an important role in the prevention of GBS colonisation in immunised women, thereby eliminating the risk of GBS transmission from the mother to the baby during pregnancy or at birth.


Asunto(s)
Infecciones Estreptocócicas , Toxoide Tetánico , Anticuerpos Antibacterianos , Formación de Anticuerpos , Células Epiteliales , Femenino , Humanos , Sueros Inmunes , Inmunoglobulina A , Inmunoglobulina G , Polisacáridos , Embarazo , Serogrupo , Infecciones Estreptocócicas/prevención & control , Streptococcus agalactiae , Vacunación , Vacunas Conjugadas
3.
Glycoconj J ; 28(7): 463-72, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21850577

RESUMEN

The introduction of type b Haemophilus influenzae conjugate vaccines into routine vaccination schedules has significantly reduced the burden of this disease; however, widespread use in developing countries is constrained by vaccine costs, and there is a need for a simple and high-yielding manufacturing process. The vaccine is composed of purified capsular polysaccharide conjugated to an immunogenic carrier protein. To improve the yield and rate of the reductive amination conjugation reaction used to make this vaccine, some of the carboxyl groups of the carrier protein, tetanus toxoid, were modified to hydrazides, which are more reactive than the ε -amine of lysine. Other reaction parameters, including the ratio of the reactants, the size of the polysaccharide, the temperature and the salt concentration, were also investigated. Experimental design was used to minimize the number of experiments required to optimize all these parameters to obtain conjugate in high yield with target characteristics. It was found that increasing the reactant ratio and decreasing the size of the polysaccharide increased the polysaccharide:protein mass ratio in the product. Temperature and salt concentration did not improve this ratio. These results are consistent with a diffusion controlled rate limiting step in the conjugation reaction. Excessive modification of tetanus toxoid with hydrazide was correlated with reduced yield and lower free polysaccharide. This was attributed to a greater tendency for precipitation, possibly due to changes in the isoelectric point. Experimental design and multiple regression helped identify key parameters to control and thereby optimize this conjugation reaction.


Asunto(s)
Infecciones por Haemophilus/prevención & control , Vacunas contra Haemophilus/síntesis química , Haemophilus influenzae tipo b/inmunología , Hidrazinas/química , Polisacáridos Bacterianos/química , Toxoide Tetánico/química , Vacunación , Vacunas Conjugadas/química , Algoritmos , Aminas/química , Aminas/inmunología , Cápsulas Bacterianas/inmunología , Países en Desarrollo , Infecciones por Haemophilus/inmunología , Vacunas contra Haemophilus/inmunología , Haemophilus influenzae tipo b/patogenicidad , Humanos , Hidrazinas/inmunología , Inmunoconjugados/química , Lisina/química , Lisina/inmunología , Polisacáridos/química , Polisacáridos/inmunología , Polisacáridos Bacterianos/inmunología , Proyectos de Investigación , Toxoide Tetánico/inmunología , Vacunas Conjugadas/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA